Latest Glaxo Stories

CHICAGO, Feb. 1, 2013 /PRNewswire/ -- Zacks Equity Research highlights WisdomTree Investments (Nasdaq:WETF) as the Bull of the Day and Joseph A. Bank (Nasdaq:JOSB) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL), Actavis, Inc. (NYSE:ACT) and GlaxoSmithKline (NYSE:GSK). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Full analysis of all these stocks is available at...

WASHINGTON, July 2, 2012 /PRNewswire/ -- Two whistleblowers represented by Phillips & Cohen LLP provided the government with overwhelming evidence that was at the heart of the government's case against GlaxoSmithKline (NYSE: GSK) and the record-setting settlement announced today. The whistleblowers - Thomas Gerahty, a former senior marketing development manager for Glaxo, and Matthew Burke, a former regional vice president -- provided invaluable insider information that Glaxo was...

WASHINGTON, April 11, 2012 /PRNewswire/ -- On April 16, the U.S. Supreme Court will hear arguments in an important case under the Fair Labor Standards Act, Christopher v. SmithKline Beecham Corp. The specific question in the case is whether pharmaceutical sales representatives are eligible to receive overtime pay. The larger issue is the deference that is owed to the U.S. Department of Labor's interpretation of that statute. The Fair Labor Standards Act and Department of Labor...

SAN DIEGO, Sept. 15 /PRNewswire/ -- Amira Pharmaceuticals, Inc. today was named one of the most promising biotech companies by FierceBiotech through its annual list, the Fierce 15. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position. A complete list of "Fierce 15" companies is available online at www.fiercebiotech.com. "The...

A panel of U.S. Food and Drug Administration advisers voted Wednesday to allow GlaxoSmithKline's diabetes drug Avandia to remain on the market, but with new restrictions due to the risky cardiovascular side effects of the controversial pill.The panel of experts voted 20-12 to retain availability of Avandia to diabetics, although 10 panelists called for limiting who can receive and prescribe the once-blockbuster medication.British drugmaker Glaxo has been hit with thousands of lawsuits from...

GlaxoSmithKline Plc stood up for its diabetes pill Avandia against U.S. advisers this week, claiming that it was safe and should stay on the market. The scientific experts assembled by the U.S. Food and Drug Administration are sorting through cases to determine whether Avandia causes heart attacks. "Follow the science where it leads and the rest will fall into place," FDA Commissioner Margaret Hamburg said in the opening of a meeting held in a packed hotel ballroom, acknowledging...

Blizzard, McCarthy & Nabers Calls on Company to Follow Suit in U.S. HOUSTON, March 4 /PRNewswire-USNewswire/ -- Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX. Despite hundreds of American consumers reporting...

Cervical cancer vaccines have gotten quite a boost since a United States advisory panel recommended the approval of GlaxoSmithKline's Cervarix, which is expected to give Merck & Co's Gardasil a run for its money.According to an overwhelmingly favorable vote by the FDA's panel of vaccine experts on Wednesday, Cervarix appears safe and effective for females ranging in ages from 10 to 25. If the FDA follow the group's recommendations, Glaxo would engage in an intense competition against...

The head of biotech research GlaxoSmithKline Plc said a new generation of "slimline" antibody medicines may be successors to current blockbusters such as Avastin and Rituxan.Ian Tomlinson headed the next-generation antibody firm Domantis until Glaxo bought it for $405 million in 2006.Now a coming wave of ultra-small antibody products capable of working in ways impossible for conventional treatments is gaining attention.Tomlinson said he thinks the next generation approaches have...

By Elisabeth Rosenthal In two years, cervical cancer has gone from obscure killer confined mostly to poor nations to the West's disease of the moment. Tens of millions of girls and young women have been vaccinated against the disease in the United States and in Europe in the two years since two vaccines were given government approval in many countries and, often, recommended for universal use among females from 11 to 26. One of the vaccines, Gardasil, from Merck, is paid for by the...